What adverse reactions may Daprostat cause?

Daprodustat (Daprodustat) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), mainly used to treat chronic kidney disease-related anemia. Although its mechanism of action by stimulating the production of endogenous erythropoietin (EPO) and improving anemia is widely recognized, it is still necessary to be alert to a series of potential adverse reactions during use. According to clinical trial and post-marketing surveillance data, the most common adverse reactions of daplestat include hypertension, thrombotic vascular events, and abdominal pain, with an incidence rate of ≥10%.

Hypertension is one of the most frequently reported adverse events during treatment with daprostat. This may be related to the drug stimulating red blood cell production and increasing blood viscosity, thereby causing an increase in blood pressure. Clinical studies have shown that some patients developed new-onset or worsened hypertension during treatment with dapoxostat. Therefore, blood pressure should be monitored regularly during treatment and antihypertensive drugs should be adjusted if necessary.

Thrombotic vascular events are also a problem that requires special attention during the treatment of daprexostat. Increased red blood cell count may lead to increased blood viscosity, thereby increasing the risk of thromboembolism, including venous thromboembolism (such as deep vein thrombosis and pulmonary embolism) and arterial thrombotic events (such as myocardial infarction and stroke). Therefore, for patients with high risk factors for thrombosis, such as patients with previous thrombosis history and cardiovascular disease, the risks and benefits need to be carefully weighed when using daprostat, and individual treatment adjustments should be made if necessary.

Abdominal pain is also a common adverse reaction. Although usually mild to moderate, it may affect treatment compliance in some patients. The specific mechanism of abdominal pain is not completely clear, but it may be related to the slight stimulation of the gastrointestinal tract by the drug or the systemic inflammatory response. Symptomatic treatment is usually used for management. If symptoms persist or worsen, it should be promptly evaluated whether the treatment plan needs to be adjusted.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat